Project Grant HT94252410058

The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...

The National Cancer Institute awarded a $1,634,811 Project Grant to Natsar Pharmaceuticals, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports the drug development of RK-33, a small molecule inhibitor of the DDX3 RNA helicase, for the treatment of triple-negative breast cancers (TNBCs). TNBCs constitute 10-25% of all breast cancers and primarily affect younger women and African-American women, with limited treatment options. Preclinical studies...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,129 to The Johns Hopkins University to conduct research on leveraging a DDX3 inhibitor, RK-33, in combination with immunotherapy to treat triple-negative breast cancer (TNBC). The goal is to alter the tumor's metabolic environment in a way that enhances the effectiveness of immunotherapy, potentially leading to an "abscopal effect" where the treatment induces regression...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Promilead, LLC to activate the TFEB protein and enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The key objectives are to: Determine how TFEB expression and activation in TNBC cells can favorably modulate tumor-associated macrophages to suppress tumor growth. Prior research has shown that TFEB has tumor suppressive roles in breast...

This federal Project Grant award, valued at $630,171.00, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award aims to develop a first-in-class targeted radiopharmaceutical therapy (RPT) for the treatment of triple-negative breast cancer (TNBC), which lacks effective hormonal therapies. The key product being developed is a novel variable new antigen receptor (VNAR) binding domain from a nurse shark that targets the c-Met receptor,...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...

This $658,561 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel class of MDM2 degraders for improved treatment of triple-negative breast cancer (TNBC). The lead compound, CH175, has shown promising anti-tumor activity in TNBC patient-derived xenograft models. The key objectives are to: 1) Optimize the CH175 scaffold to increase binding to the MDM2 ring domain and improve anti-TNBC potency, and 2)...

This $135,993 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Duke University to investigate the role of the ABL kinase-regulated HIF-1α-TAZ signaling pathway in promoting brain metastasis in triple-negative breast cancer (TNBC). The goal is to evaluate whether ABL-dependent activation of HIF-1 and TAZ leads to enhanced expression of unique transcriptional targets that promote brain metastasis in TNBC, and whether...

This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...